Multiple Myeloma Clinical Trial

Clinical Trial Finder Multiple Myeloma Trials

Descartes-11 in Multiple Myeloma

See Locations Near You

Summary

This Phase I/2 study will test the safety and anti-myeloma activity of ascending doses of Descartes-11 (autologous CD8+ T-cells expressing an anti-BCMA chimeric antigen receptor) in eligible patients with active multiple myeloma.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Active multiple myeloma that is refractory after at least 2 prior lines of therapy;
measurable disease;
adequate vital organ function; and
no active infection.

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

25

Study ID:

NCT03994705

Recruitment Status:

Active, not recruiting

Sponsor:

Cartesian Therapeutics

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 2 Locations for this study

See Locations Near You

Center for Cancer and Blood Disorders
Bethesda Maryland, 20817, United States
Medical College of Wisconsin
Madison Wisconsin, 53226, United States

How clear is this clinincal trial information?

Study is for people with:

Multiple Myeloma

Phase:

Phase 1

Estimated Enrollment:

25

Study ID:

NCT03994705

Recruitment Status:

Active, not recruiting

Sponsor:


Cartesian Therapeutics

How clear is this clinincal trial information?

Clinical Trial Resources

Why I’d Choose a Clinical Trial For Myself
SurvivorNet’s Guide To Clinical Trials: What Are They And Are They Right for You?
Clinical Trials Can be Life-Saving for Some
×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider